会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • INTEGRIN CD18 IS A NOVEL STROMAL STEM CELL MARKER AND FUNCTIONS TO PROMOTE OSTEOGENESIS
    • INTEGRIN CD18是一种新的结构干细胞标记和功能来促进骨质疏松
    • WO2006029347A3
    • 2006-12-07
    • PCT/US2005032220
    • 2005-09-06
    • UNIV MARYLANDZHANG LIMIURA YASUOSHI SONGTAO
    • ZHANG LIMIURA YASUOSHI SONGTAO
    • G01N33/567A01N1/02C12N5/077C12N5/0775
    • C12N5/0663A61K35/28A61K48/00A61K2035/124G01N33/56966Y10T436/25375
    • The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the BMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.
    • 本发明涉及用于从骨髓细胞,脂肪细胞或外周血中选择富含BMSSC的细胞群的新型骨髓基质干细胞(BMSSC)标记物CD18。 本发明还涉及使用本领域已知的技术例如荧光辅助细胞分选,免疫磁性法,流量显微荧光法,免疫荧光,免疫过氧化物酶,基于CD18在其表面上的选择性表达来选择富集BMSSC的细胞群的方法 染色,放射免疫测定和免疫亲和层析。 本发明进一步针对基于CD18表达分离的BMSSC及其用于治疗各种疾病的用途。 一方面,用具有CD18正常基因的载体转化BMSSC,并施用转化的BMSSC以治疗涉及CD18 CD18表达异常表达的骨退行性疾病和骨疾病。
    • 4. 发明申请
    • ANIMAL MODEL SUBCUTANEOUSLY TRANSPLANTED WITH MESENCHYMAL STEM CELLS
    • 用MESENCHYMAL STEM CELLS传播的动物模型
    • WO2010068707A3
    • 2010-08-26
    • PCT/US2009067398
    • 2009-12-09
    • UNIV SOUTHERN CALIFORNIASHI SONGTAOYAMAZA TAKAYOSHIAKIYAMA KENTARO
    • SHI SONGTAOYAMAZA TAKAYOSHIAKIYAMA KENTARO
    • A01K67/027
    • A01K67/0275A01K2227/105A01K2267/03
    • This invention discloses a stem cell modified animal model useful as a research tool for investigating aging-related degeneration processes and treatments. The animal model is preferably a rodent subcutaneously transplanted with a mesenchymal stem cell capable of generating a functional bone or marrow element. Also provided are a method for extending the lifespan and improving the quality of life of a subject by subcutaneously transplanting a plurality of mesenchymal stem cells to the subject, wherein the mesenchymal stem cells are capable of generating a functional bone or marrow element. Compositions and source of stem cells suitable for use with the methods of this invention, including stem cells from human exfoliated deciduous teeth (SHED), are also disclosed. Further disclosed is a method for identifying progenitor bone marrow mesenchymal stem cells, and a method for treating SLE-like autoimmune diseases by infusion of mesenchymal stem cells.
    • 本发明公开了一种干细胞修饰动物模型,可用作研究老化相关变性过程和治疗的研究工具。 动物模型优选是皮下移植能够产生功能性骨或骨髓元件的间充质干细胞的啮齿动物。 还提供了一种通过将多个间充质干细胞皮下移植到受试者来延长使用寿命并提高受试者的生活质量的方法,其中间充质干细胞能够产生功能性骨或骨髓元件。 还公开了适用于本发明方法的干细胞的组合物和来源,包括来自人脱落落叶牙(SHED)的干细胞。 进一步公开了一种鉴定祖细胞骨髓间充质干细胞的方法,以及通过输注间充质干细胞治疗SLE样自身免疫性疾病的方法。
    • 6. 发明申请
    • INTEGRIN CD18 IS A NOVEL STROMAL STEM CELL MARKER AND FUNCTIONS TO PROMOTE OSTEOGENESIS
    • INTEGRIN CD18是一种新型的STROMAL STEM细胞标记物和促进成骨细胞增殖的功能
    • WO2006029347A2
    • 2006-03-16
    • PCT/US2005/032220
    • 2005-09-06
    • UNIVERSITY OF MARYLAND, BALTIMOREZHANG, LiMIURA, YasuoSHI, Songtao
    • ZHANG, LiMIURA, YasuoSHI, Songtao
    • A61K48/00
    • C12N5/0663A61K35/28A61K48/00A61K2035/124G01N33/56966Y10T436/25375
    • The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the BMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.
    • 本发明涉及一种新的骨髓基质干细胞(BMSSC)标记CD18,用于从骨髓细胞,脂肪细胞或外周血中选择富含BMSSC的细胞群 血液。 本发明还涉及使用本领域已知的技术如荧光辅助细胞分选,免疫磁性方法,流式微量荧光测定法,免疫荧光法,免疫过氧化物酶 染色,放射免疫测定和免疫亲和层析。 本发明进一步涉及基于CD18表达分离的BMSSCs及其用于治疗各种疾病的用途。 一方面,用具有正常CD18基因的载体转化BMSSC,并且施用转化的BMSSC以治疗骨退行性疾病和涉及CD18的CD18表达异常表达的骨疾病。